Allogeneic stem cells, clinical transplantation and the origins of regenerative medicine

Terry B. Strom, Loren Field, Loren J. Field

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The therapeutic use of stem cells is a popular topic that is often in the news. Stem cells are of particular relevance to the transplant community, as stem cell-based therapies will probably be derived from allogeneic sources. Stem cells may be obtained from somatic (adult) cell or embryonic cell origin. The ability to establish stem cell lines in vitro means that we can standardize therapeutic grafting applications, which is a prerequisite for the widespread application of stem cell therapy. This attribute also means that we can produce large batches of allogeneic terminally differentiated cells, which can be administered to patients. Three important barriers to the deployment of this therapy currently exist; in addition to the many ethical issues facing the widespread use of stem cell therapy, it is also important to develop methods to derive pure terminally differentiated cells for transplantation and to induce immune tolerance to these allogeneic cells, as daily anti-rejection therapy cannot be justified for many potential applications.

Original languageEnglish (US)
Article number00000387
Pages (from-to)601-605
Number of pages5
JournalCurrent Opinion in Immunology
Volume14
Issue number5
DOIs
StatePublished - 2002

Fingerprint

Regenerative Medicine
Stem Cell Transplantation
Stem Cells
Cell- and Tissue-Based Therapy
Immune Tolerance
Cell Transplantation
Therapeutic Uses
Ethics
Immunosuppression
Transplants
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Allogeneic stem cells, clinical transplantation and the origins of regenerative medicine. / Strom, Terry B.; Field, Loren; Field, Loren J.

In: Current Opinion in Immunology, Vol. 14, No. 5, 00000387, 2002, p. 601-605.

Research output: Contribution to journalArticle

@article{91f1a2439ef24142a2c301420fcbffa2,
title = "Allogeneic stem cells, clinical transplantation and the origins of regenerative medicine",
abstract = "The therapeutic use of stem cells is a popular topic that is often in the news. Stem cells are of particular relevance to the transplant community, as stem cell-based therapies will probably be derived from allogeneic sources. Stem cells may be obtained from somatic (adult) cell or embryonic cell origin. The ability to establish stem cell lines in vitro means that we can standardize therapeutic grafting applications, which is a prerequisite for the widespread application of stem cell therapy. This attribute also means that we can produce large batches of allogeneic terminally differentiated cells, which can be administered to patients. Three important barriers to the deployment of this therapy currently exist; in addition to the many ethical issues facing the widespread use of stem cell therapy, it is also important to develop methods to derive pure terminally differentiated cells for transplantation and to induce immune tolerance to these allogeneic cells, as daily anti-rejection therapy cannot be justified for many potential applications.",
author = "Strom, {Terry B.} and Loren Field and Field, {Loren J.}",
year = "2002",
doi = "10.1016/S0952-7915(02)00387-4",
language = "English (US)",
volume = "14",
pages = "601--605",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Allogeneic stem cells, clinical transplantation and the origins of regenerative medicine

AU - Strom, Terry B.

AU - Field, Loren

AU - Field, Loren J.

PY - 2002

Y1 - 2002

N2 - The therapeutic use of stem cells is a popular topic that is often in the news. Stem cells are of particular relevance to the transplant community, as stem cell-based therapies will probably be derived from allogeneic sources. Stem cells may be obtained from somatic (adult) cell or embryonic cell origin. The ability to establish stem cell lines in vitro means that we can standardize therapeutic grafting applications, which is a prerequisite for the widespread application of stem cell therapy. This attribute also means that we can produce large batches of allogeneic terminally differentiated cells, which can be administered to patients. Three important barriers to the deployment of this therapy currently exist; in addition to the many ethical issues facing the widespread use of stem cell therapy, it is also important to develop methods to derive pure terminally differentiated cells for transplantation and to induce immune tolerance to these allogeneic cells, as daily anti-rejection therapy cannot be justified for many potential applications.

AB - The therapeutic use of stem cells is a popular topic that is often in the news. Stem cells are of particular relevance to the transplant community, as stem cell-based therapies will probably be derived from allogeneic sources. Stem cells may be obtained from somatic (adult) cell or embryonic cell origin. The ability to establish stem cell lines in vitro means that we can standardize therapeutic grafting applications, which is a prerequisite for the widespread application of stem cell therapy. This attribute also means that we can produce large batches of allogeneic terminally differentiated cells, which can be administered to patients. Three important barriers to the deployment of this therapy currently exist; in addition to the many ethical issues facing the widespread use of stem cell therapy, it is also important to develop methods to derive pure terminally differentiated cells for transplantation and to induce immune tolerance to these allogeneic cells, as daily anti-rejection therapy cannot be justified for many potential applications.

UR - http://www.scopus.com/inward/record.url?scp=0036775071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036775071&partnerID=8YFLogxK

U2 - 10.1016/S0952-7915(02)00387-4

DO - 10.1016/S0952-7915(02)00387-4

M3 - Article

C2 - 12183159

AN - SCOPUS:0036775071

VL - 14

SP - 601

EP - 605

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 5

M1 - 00000387

ER -